WCN26-2254 IgA NEPHROPATHY FOLLOWING RISANKIZUMAB THERAPY FOR PSORIATIC ARTHRITIS: A CASE REPORT

Read full text Summarise with VIRAT
Authors: Motohiro Yagasaki, Koshi Yamada, Takeo Koshida, Miyuki Takagi, Harumi Saeki, Takashi Kobayashi, Masao Kihara, Tomohito Gohda, Yusuke Suzuki
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) has been characterized as an autoimmune disease in which IgA1-containing mesangial immunodeposits are derived from circulating immune complexes composed of galactose-deficient IgA1 (Gd-IgA1), the autoantigen, bound by Gd-IgA1–specific autoantibodies. According to the multi-hit pathogenesis model, overproduction of Gd-IgA1 represents the first hit and plays a central role in disease development. Associations between biologic agents and the onset of IgAN have been suggested, with cases reported following treatment with TNF-α inhibitors and immune checkpoint inhibitors, although the underlying mechanisms remain unclear.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Vasculitis and related conditions Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106184–106184
Publication date
25 March 2026
Language
EN